Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hepatitis A

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,495 result(s) found for: Hepatitis A. Displaying page 3 of 75.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-000828-14 Sponsor Protocol Number: VX05-950-104EU Start Date*: 2006-06-13
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®), With and Without Ribavirin (Copegus®) in Subjects with Hepatitis C
    Medical condition: Hepatitis C virus (HCV) infection
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019744 Hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003340-72 Sponsor Protocol Number: 5172-39 Start Date*: 2013-05-14
    Sponsor Name:Merck Sharp & Dohme Corp.
    Full Title: A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of MK-5172 in Combination with Ribavirin (RBV) in Subjects with Chronic Hepatitis C Virus Infection
    Medical condition: Chronic Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2012-004154-28 Sponsor Protocol Number: GS-US-334-0124 Start Date*: 2013-02-15
    Sponsor Name:Gilead Sciences Inc
    Full Title: A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-i...
    Medical condition: Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    20.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-005808-14 Sponsor Protocol Number: TMC435HPC1002 Start Date*: 2012-03-06
    Sponsor Name:Janssen R&D Ireland
    Full Title: A Phase I, open-label, randomized, 3-panel, 3-way crossover trial in healthy adult subjects to assess the relative bioavailability of TMC435 following administration of 2 liquid formulations or 2 d...
    Medical condition: Hepatitis C Virus (HCV) genotype-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002695-17 Sponsor Protocol Number: DEB-025-HCV-203 Start Date*: 2006-09-21
    Sponsor Name:DEBIOPHARM S.A.
    Full Title: A multi-centre, randomised, double-blind, placebo-controlled escalating dose ranging phase II study on the efficacy of DEBIO-025 to reduce HCV viral load in combination with PEGASYS 180 g/week i...
    Medical condition: treatment na ve patients with chronic hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019744 Hepatitis C LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005161-11 Sponsor Protocol Number: 116/2005U/Sper Start Date*: 2005-08-01
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Treatment with leucocytic interferon-alpha more ribavirine towards peg-interferon to reduced doses more ribavirine in patients affections from positive chronic hepatitis HCV that in course of arran...
    Medical condition: CHRONIC HEPATITIS FROM VIRUS C
    Disease: Version SOC Term Classification Code Term Level
    6.1 10019744 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-005554-74 Sponsor Protocol Number: MORE Start Date*: 2007-04-09
    Sponsor Name:Fundació de LLuita contra la Sida
    Full Title: Estudio piloto para evaluar la eficacia y seguridad en las 12 primeras semanas de altas dosis de Ribavirina (1600 mg/día) con apoyo de Epoetina β (450 UI/kg/semana) en la terapia de inducción en pa...
    Medical condition: Hepatitis C crónica
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    9.1 10002725 Anti-HIV positive LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005698-76 Sponsor Protocol Number: HLS02/2007 Start Date*: 2007-11-29
    Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
    Full Title: Evaluation of chronic hepatitis C treatment with PEG-IFN ALFA-2a and ribavirin in HIV-positive subjects with persistently normal transaminase levels.
    Medical condition: Treatment of adult patients with hystologically demonstrated chronic C hepatitis without hepatic failure and HCV-RNA positive, treatment of patients with normal ALT and with HIV/HCV co-infection.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003941-27 Sponsor Protocol Number: UMCN-AKF16.06/Hep-NED004 Start Date*: 2017-12-14
    Sponsor Name:Radboud University Medical Center
    Full Title: Bioequivalence study of CRUshed Sofosbuvir/velpAtasvir compareD to the wholE tablet (CRUSADE-1)/Hep-NED004
    Medical condition: hepatitis C virus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-004212-64 Sponsor Protocol Number: IMC-I109V-101 Start Date*: 2020-08-12
    Sponsor Name:Immunocore Ltd
    Full Title: An Open-label Study Evaluating the Safety, Antiviral Activity, and Pharmacokinetics of IMC-I109V in HLA-A*02:01 Positive Patients with Chronic HBV who are Non-Cirrhotic, Hepatitis B e Antigen-nega...
    Medical condition: chronic hepatitis B virus (HBV) infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10019182 HBV LLT
    20.0 100000004848 10019743 Hepatitis B virus (HBV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) PL (Prematurely Ended) RO (Completed) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-020931-37 Sponsor Protocol Number: IG0907 Start Date*: 2010-10-01
    Sponsor Name:GRIFOLS S.A.
    Full Title: EFFICACY AND SAFETY OF NIULIVA FOR THE PREVENTION OF HEPATITIS B VIRUS RECURRENCE IN NEWLY ORTHOTOPIC LIVER TRANSPLANT RECIPIENTS
    Medical condition: HBV induced liver disease.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019731 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002008-28 Sponsor Protocol Number: 2017-002008-28 Start Date*: 2017-12-21
    Sponsor Name:Region Skåne
    Full Title: A prospective open label study to evaluate treatment of chronic HCV infection with glecaprevir/pibrentasvir in PWID attending a needle exchange program
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003460-36 Sponsor Protocol Number: GS-US-367-1172 Start Date*: 2016-02-12
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpa...
    Medical condition: Chronic Hepatitis C virus infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    19.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-002996-12 Sponsor Protocol Number: GS-US-367-1173 Start Date*: 2016-02-16
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir f...
    Medical condition: Chronic Hepatitis C virus infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    18.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003167-10 Sponsor Protocol Number: GS-US-367-1170 Start Date*: 2016-02-16
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir ...
    Medical condition: Chronic Hepatitis C virus infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    18.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003455-21 Sponsor Protocol Number: GS-US-367-1171 Start Date*: 2016-02-12
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Di...
    Medical condition: Chronic Hepatitis C virus infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    18.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-002897-30 Sponsor Protocol Number: GS-US-334-0154 Start Date*: 2014-01-10
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Phase 2b Open-Label Study of 200 mg or 400 mg Sofosbuvir+RBV for 24 Weeks in Genotype 1 or 3 HCV-Infected Subjects with Renal Insufficiency
    Medical condition: Chronic Hepatitis C virus infection
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    17.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-002221-37 Sponsor Protocol Number: PA-IT72-2012 Start Date*: 2018-11-12
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO “PAOLO GIACCONE” DI PALERMO
    Full Title: Glecaprevir/ pibrentasvir plus fixed-dose combination for 6 weeks in patients with acute hepatitis C virus: a pilot study.
    Medical condition: Acute HCV infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10047457 Viral hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000699-91 Sponsor Protocol Number: RACHE Start Date*: 2015-09-14
    Sponsor Name:Fundació Hospital Vall Hebron Institut de Recerca
    Full Title: Two treatment strategies with Ribavirin for Chronic Hepatitis E and severe acute forms randomized study
    Medical condition: Chronic Hepatitis E
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10019768 Hepatitis E PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-023498-20 Sponsor Protocol Number: P07614 Start Date*: 2011-11-14
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Assessment of the Pharmacokinetics of Boceprevir in Pediatric Subjects with Chronic Hepatitis C Genotype 1 (Phase 1b)
    Medical condition: Hepatitis type C (genotype I) virus infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) PL (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 13:46:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA